GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...

UK-based GlaxoSmithKline PLC (GB:GSK) hits a key milestone in its ovarian cancer trial, testing Zejula (niraparib) and Jemperli (dostarlimab). The company announced that its FIRST-ENGOT-OV44 phase ...

GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of ...

GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli (dostarlimab) combination in treating first-line advanced ovarian cancer met ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...

GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...